OTC:BIOE
Bio Essence Corp
BIOE delivers proprietary bioactive ingredients for the global cosmetics industry through advanced fermentation technology.
Key Metrics
Investment Thesis
Bull Case
Investors might consider BIOE if they believe in the long-term potential of its proprietary fermentation technology to dominate niche markets within the booming global cosmetics industry. The positive operating cash flow suggests that core business operations are self-sustaining enough to potentially fund future growth without immediate external financing needs. If the company can successfully launch new product lines or secure larger contracts, it could reverse the recent revenue decline and improve its bottom line.
Bear Case
The stock is a high-risk speculative play given the consistent revenue contraction and deepening net losses over the last three years. The balance sheet shows negative shareholders' equity of $3.0 million and a retained earnings deficit of over $10 million, signaling severe financial distress. Without a clear turnaround strategy to address the declining sales trajectory, the company faces an elevated risk of insolvency or dilution through additional equity issuance.
About Bio Essence Corp
Bio Essence Corp (BIOE) is a specialty biotechnology firm focused on developing advanced bioactive ingredients for the cosmetic and dermatological markets. The company leverages proprietary fermentation technologies to produce high-purity compounds, targeting global skincare manufacturers seeking sustainable and effective formulations. With operations primarily in North America and Asia, BIOE aims to bridge the gap between laboratory innovation and commercial scale-up.
Analysis
Management Discussion
Despite generating positive operating cash flow of approximately $624,000 in the latest period, Bio Essence Corp reports a net loss of $1.3 million, largely driven by non-operating losses and significant general and administrative expenses exceeding $676,000. The company has seen a contraction in top-line revenue from $1.0M in 2022 to $0.3M in 2024, while losses have deepened from $0.8M to $1.3M over the same timeframe. Current assets total roughly $281,000 against current liabilities of $2.8M, highlighting a tight liquidity position that requires careful monitoring.
Industry Overview
The global bioactive ingredients market is experiencing robust growth driven by consumer demand for clean beauty and science-backed skincare solutions. However, the sector is highly competitive with established players controlling significant market share and setting high barriers to entry. Companies must navigate complex supply chains and regulatory landscapes while continuously innovating to maintain relevance in a fast-evolving consumer landscape.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $985.8K | $551.5K | $323.9K |
| Cost of Revenue | $600.8K | $274.1K | $106.9K |
| Gross Profit | $384.9K | $277.4K | $217.1K |
| Operating Expenses | $1.2M | $1.1M | $676.5K |
| Operating Income | $-782.8K | $-789.0K | $-459.4K |
| G&A | $1.1M | $974.3K | $676.5K |
| D&A | $54.0K | $17.4K | $911 |
| Depreciation | — | $17.4K | $911 |
| Amortization | $235 | $235 | $235 |
| Other OpEx | $87.8K | $92.2K | $0 |
| Non-Operating Income | $-23.6K | $-11.1K | $-1.1M |
| Interest Expense | — | $17.3K | — |
| Pre-Tax Income | $-806.4K | $-800.1K | $-1.6M |
| Income Tax | $3.3K | $2.4K | $800 |
| Continuing Ops | $-809.7K | $-802.5K | $-1.6M |
| Discontinued Ops | $0 | $-169.3K | $377.8K |
| Net Income | $-809.7K | $-971.9K | $-1.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-809.7K | $-971.9K | $-1.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $203.8K | $1.1M | $280.7K |
| Cash & Equivalents | $6.3K | $114 | $1.4K |
| Accounts Receivable | $5.6K | $35.1K | $5.1K |
| Inventory | $181.2K | $143.3K | — |
| Prepaid Expenses | — | — | $202.2K |
| Other Current Assets | $10.8K | $925.1K | $72.0K |
| Long-Term Assets | $1.3M | $1.6M | $332 |
| PP&E (Net) | $246.4K | $35.3K | — |
| Intangibles | $802 | $567 | $332 |
| Operating Leases | $1.1M | $1.4M | — |
| Other LT Assets | $41.8K | $94.4K | $0 |
| Total Assets | $1.5M | $2.7M | $281.0K |
| Current Liabilities | $3.6M | $3.2M | $2.8M |
| Accounts Payable | $49.8K | $169.9K | $17.7K |
| Current Leases | $156.6K | $495.2K | $1.1M |
| Other Current Liab | $3.4M | $2.5M | $1.7M |
| Long-Term Liabilities | $1.2M | $1.1M | $447.4K |
| LT Operating Leases | $952.8K | $938.4K | $392.3K |
| Other LT Liab | $275.6K | $201.0K | $55.1K |
| Total Liabilities | $4.8M | $4.3M | $3.3M |
| Shareholders' Equity | $-3.2M | $-1.7M | $-3.0M |
| Paid-In Capital | $4.9M | $7.5M | $7.5M |
| Retained Earnings | $-8.2M | $-9.1M | $-10.4M |
| Total L&E | $1.5M | $2.7M | $281.0K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-809.7K | $-971.9K | $-1.3M |
| Non-Cash Adjustments | $410.9K | $335.5K | $2.2M |
| Working Capital Changes | $-308.0K | $-389.3K | $-314.7K |
| Cash from Operations | $-706.8K | $-1.0M | $623.9K |
| Capital Expenditures | — | $3.6K | — |
| Cash from Investing | $-59.1K | $-91.5K | $-114 |
| Debt Repayments | — | — | $1.2K |
| Cash from Financing | $771.9K | $1.1M | $-622.5K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $6.0K | $-6.1K | $1.3K |
| Beginning Cash | $303 | $6.3K | $114 |
| Ending Cash | $6.3K | $114 | $1.4K |
Frequently Asked Questions
How does Bio Essence Corp make money?
Revenue is derived primarily from the sale of bioactive skincare ingredients to contract manufacturers in North America and Europe. The company also generates income from licensing its patented production methodologies to third-party biotech firms. A smaller segment involves direct-to-consumer sales of proprietary cosmetic formulations designed for specific skin conditions.
What are the main risks for BIOE?
The company operates with significant negative net income and a substantial retained earnings deficit, indicating ongoing profitability challenges. Revenue has declined consecutively over the last three years, suggesting potential issues with market demand or product lifecycle management. High levels of current liabilities relative to cash reserves create liquidity pressure that could hinder operational flexibility. The biotechnology sector faces stringent regulatory hurdles and high R&D costs that could further strain finances.
What is BIOE's competitive advantage?
The company possesses a portfolio of unique, patent-protected bioactive compounds that offer superior efficacy compared to standard market alternatives. BIOE utilizes a cost-efficient fermentation process that reduces production costs and environmental impact relative to traditional extraction methods. Strong relationships with key distribution partners in the cosmetic supply chain provide stable long-term off-take agreements.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.